Owkin: The company raised $80 million of Series B1 venture funding in a deal led by Bristol-Myers Squibb on June 9, 2022. The company is a developer of machine learning tools designed to augment medical and biological research.
Code Bio: The company raised $75 million through a combination of Series A-1 and Series A-2 venture funding in a deal led by Northpond Ventures on June 9, 2022, putting the company’s pre-money valuation at $50 million. UPMC Enterprises, and 8 other investors participated in the round. The company is a developer of a non-viral gene therapy designed to treat serious and life-threatening genetic diseases.
ImmunOs Therapeutics: The company raised $74 million of Series B venture funding in a deal led by Gimv, Samsara BioCapital and Lightspeed Venture Partners on June 7, 2022. Pfizer Ventures, Mission BioCapital, BioMedPartners, PEAK6 Strategic Capital, Fiscus Ventures, Schroders Capital and Gl Capital also participated in the round. The company is a developer of novel human immunomodulatory proteins and drugs designed to treat cancer and autoimmune diseases.
Ancora Biotech: The company raised $60 million of Series A venture funding in a deal led by SR One and Lightspeed Venture Partners on June 9, 2022. The company is a developer of antibody biotherapeutics drugs intended to develop a treatment for several life-threatening diseases.
Corvia: The company raised $54 million of venture funding from undisclosed investors on June 9, 2022. The company is a developer of a transcatheter device designed to reduce the symptoms or slow the progression of heart failure.
Bicycle Health: The company raised $50 million of Series B venture funding in a deal led by InterAlpen Partners on June 7, 2022. Questa Capital, City Light Capital and Frist Cressey Ventures also participated in the round. The company is a developer of an online healthcare platform for virtual opioid addiction treatment.
Peptone: The company raised $40 million of Series A venture funding in a deal led by F-Prime Capital and Bessemer Venture Partners on June 9, 2022. Hoxton Ventures, dRx Capital and Walden Catalyst also participated in the round. The company is an operator of a protein intelligence company intended to accelerate protein lead design and optimization through artificial intelligence.
L7 Informatics: The company received $38 million of development capital from Banneker Partners on June 7, 2022. The company is a developer of a regulatory compliance platform intended to improve the scientific process by streamlining process and data management.
Moon Surgical: The company raised $31.3 million of Series A venture funding in a deal led by GT Healthcare Capital Partners on June 7, 2022. Johnson & Johnson Innovation – JJDC, Cathay Capital Private Equity, Sofinnova Partners, Yann Fleureau, Siddarth Satish, Sacha Loiseau, Richard Leparmentier, and other undisclosed investors also participated in the round. The company is a developer of surgical devices designed to facilitate access to minimally invasive surgery techniques and optimize operating room resources.
Ariceum Therapeutics: The company raised EUR 25 million of Series A venture funding in a deal co-led by HealthCap and EQT Life Sciences on June 8, 2022. Pureos Bioventures also participated in the round. The company is a developer of novel drugs for systemic targeted radiotherapy (STR) focused on the diagnosis and precision treatment of neuroendocrine and hard-to-treat cancers.
PineTree Therapeutics: The company raised $23.5 million of Series A1 venture funding from SK Securities, J Curve Investment and Samho Green Investment on June 7, 2022. DSC Investment, InterVest and SJ Investment Partners also participated in the round. The company is a developer of biological therapeutics technology designed to treat unmet needs in oncology and infectious diseases.
Centrexion Therapeutics: The company raised $16.5 million of venture funding in the form of convertible debt from undisclosed investors on June 8, 2022. The company is an operator of a clinical-stage biopharmaceutical company intended to address the unmet medical need for the treatment of chronic pain.
Reprieve Cardiovascular: The company raised $15 million of Series A venture funding from Lightstone Ventures and other undisclosed investors on June 7, 2022, putting the company’s pre-money valuation at $23 million. The company is a developer of an acute decompensated heart failure (ADHF) treatment medical device.
Revalesio: The company raised $12 million of venture funding from undisclosed investors on June 9, 2022. The company is a developer of an anti-inflammatory therapeutic drug designed to treat a variety of neurological diseases.
NFlection Therapeutics: The company raised $10 million of venture funding from undisclosed investors on June 9, 2022. The company is a developer of novel therapies designed to cure rare disorders driven by aberrant activation of the RAS pathway.
Rhinostics: The company raised an estimated $8 million of Series A2 venture funding in a deal led by Shadow Capital on June 7, 2022, putting the company’s pre-money valuation at $22 million. Avestria Ventures and Covid Apollo also participated in the round. The company is a developer of sample collection kits for tests like COVID-19 designed to increase the efficiency, accuracy, and safety of laboratories.
AnaBios: The company raised $6.5 million of Series C2 venture funding from Ampersand Capital Partners and other undisclosed investors on June 9, 2022, putting the company’s pre-money valuation at $28 million. The company is a provider of drug discovery insights intended to accelerate the development of novel therapeutics.
